← FDATracker
HomeAdverse Events

USTEKINUMAB Adverse Event: Malignant melanoma in situ

USTEKINUMAB Adverse Event: Malignant melanoma in situ is one of 4,500 adverse events in the FDATracker dataset. Key details — Primary drug: USTEKINUMAB; Product category: Drug; Primary reaction: Malignant melanoma in situ.

Primary drugUSTEKINUMAB
Product categoryDrug
Primary reactionMalignant melanoma in situ
All reactionsMalignant melanoma in situ
SeriousnessSerious
Patient outcomeRecovered/Resolved
Patient sexMale
All drugs reportedUSTEKINUMAB
Reporter countryUS
Reporter type3
Report date20140313
Report ID10007196

🔍 Search all adverse events →